

15

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 088/02319
In Re Application Of: Amir LOSHA KOVE et al.			
Serial No. 09/936,789	Filing Date September 17, 2001	Examiner JACKSON, Gary	Group Art Unit 3731
Title: VASCULAR CLOSURE DEVICE			
RECEIVED			
Box 313(6)		Address to: Assistant Commissioner for Patents Washington, D.C. 20231	APR 29 2003 OFFICE OF PETITIONS
37 CFR 1.97(b)			
1. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.			
37 CFR 1.97(c)			
2. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: (In light of the concurrent filing of an RCE.) <input type="checkbox"/> the statement specified in 37 CFR 1.97(e);			
OR			
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).			

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In regard to the application of: Amir LOSHAKOVE et al.

Serial No : 09/936,789 Group Art Unit: 3731
Filing Date : September 17, 2001 Examiner: JACKSON, G.
For : Vascular Closure Device

SECOND SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents and Trademarks
Washington, DC 20231

RECEIVED

APR 29 2003

Sir:

OFFICE OF PETITIONS

In conjunction with the present Petition for Withdrawal from Issue and Request for Continued Examination (RCE,) applicants respectfully direct the attention of the Examiner to publications not previously cited in this application.

The Examiner is respectfully requested to review and consider this art.

Further, in order to comply with discretionary regulations 37 CFR 1.97 and 1.98, attached is Form PTO-1449 listing the cited art. Also attached are copies¹ of the art. This art contains information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

Applicants wish to point out that item 2 is cited in the Office Action dated March 12, 2003 of the U.S. parent case No. 09/701,523. (Note: U.S. Patent No. 4,997,439 was cited by the Examiner in a Notice of Allowance dated December 16, 2002 and U.S. Patent No. 6,197,042 cannot be cited herewith since it was filed after the international filing date of the present application.) Copy of item 2 is provided herewith.

In accordance with MPEP §609 it is requested that each document cited [including any mentioned in Applicants' specification which is not repeated on the attached (or prior) PTO-1449 form(s)] be given thorough consideration and be cited of record in the prosecution history of the present application by initialing on the PTO-1449 form, so that it will appear on the face of the patent issuing on the present application, even if the Examiner does not

¹ If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached, it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such an equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited then none is known to the undersigned.

consider it sufficiently pertinent to use in a rejection, or otherwise does not believe that the guidelines for citation have been fully complied with.

The present Information Disclosure Statement is being submitted in compliance with 37 C.F.R. §1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 C.F.R. §1.104(a), and in the course of such search will review for relevance every document cited on the attached form.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,
Amir LOSHAKOVE et al.

A handwritten signature in dark ink, appearing to read 'Amir LOSHAKOVE', is written over a horizontal line.

Maier FENSTER,
Registration No. 41,016

April 28, 2003
William H. Dippert, Esq.
Reed Smith LLP
599 Lexington Avenue, 29th Floor
New York, NY 10022-7650

Tel: (212) 521-5400